Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 06/03 03:59:59 pm
65.61 EUR   +2.61%
09:10aBAYER AG : Buy rating from Morgan Stanley
MD
06/02BAYER AG : Berenberg reiterates its Buy rating
MD
05/29BAYER AG : Gets a Buy rating from Bernstein
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : says glyphosate settlement talks delayed by coronavirus - Handelsblatt

share with twitter share with LinkedIn share with facebook
share via e-mail
04/02/2020 | 05:09am EDT
FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

Talks between Bayer AG and plaintiff lawyers to settle claims that the German company's glyphosate-based weedkillers cause cancer have been slowed by the coronavirus pandemic, Bayer's Chief Executive told daily Handelsblatt.

"This is about currently not being able to meet in person for talks. All this of course slows down the negotiations," CEO Werner Baumann told the newspaper in an interview published on Thursday.

Court-appointed mediator Ken Feinberg told Reuters last month that the talks were slowed by the pandemic.

In the Handelsblatt interview, CEO Baumann reiterated remarks he made at the end of February that he was under no time pressure to strike a settlement deal and that he would not submit to a schedule or deadline.

(Reporting by Ludwig Burger and Patricia Weiss; Editing by Michelle Martin)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
09:10aBAYER AG : Buy rating from Morgan Stanley
MD
06/02BAYER AG : Berenberg reiterates its Buy rating
MD
05/29BAYER AG : Gets a Buy rating from Bernstein
MD
05/29BAYER : Efficacy of Vitrakvi™ (larotrectinib) further established with con..
PU
05/29BAYER : Elanco proposes divestments of some animal health products in Bayer acqu..
AQ
05/28TCR-2 Therapeutics Hires Key Business Development and Regulatory Affairs Cell..
AQ
05/28FCA Gives Guidance For Common PM(NOC) Trials Involving Multiple Actions
AQ
05/27German chemicals industry sees coronavirus hitting 2020 revenue
RE
05/27Rising Swiss rivalry as Roche and Novartis target same diseases
RE
05/26GLOBAL MARKETS LIVE: Labs step up efforts to find coronavirus vaccine
More news
Financials
Sales 2020 44 282 M 49 734 M 49 734 M
Net income 2020 4 544 M 5 103 M 5 103 M
Net Debt 2020 29 621 M 33 267 M 33 267 M
P/E ratio 2020 14,9x
Yield 2020 4,47%
Capitalization 64 172 M 72 071 M 72 073 M
EV / Sales 2019
EV / Sales 2020 2,12x
Nbr of Employees 102 201
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,44 €
Last Close Price 65,32 €
Spread / Highest target 68,4%
Spread / Average Target 23,1%
Spread / Lowest Target -58,7%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Paul Achleitner Member-Supervisory Board
Reiner Hoffmann Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-12.18%70 264
JOHNSON & JOHNSON1.63%390 579
ROCHE HOLDING AG6.64%296 977
MERCK & CO., INC.-11.12%204 048
PFIZER, INC.-7.71%200 863
NOVARTIS AG-10.13%189 331